He noted previous CPGs had focused extensively on diabetes tech and highlighted the value of using this session to also address broader aspects of diabetes, particularly Type 2. Key Updates: • 2024–25 National Funding Impact: o Central funding enabled onboarding of 2,100 additional patients onto closed loop systems. o 50% of these were under-18s, aligning with the Scottish Government’s policy aim to expand paediatric access. o 80% predicted uptake of closed loop systems among under-18s. o The National Onboarding Team has been a critical success, onboarding 1,000 patients in 9 months with 2.5 full-time educators, in partnership with industry. ▪ Achieved 99.5% performance and 100% satisfaction. ▪ Results to be showcased in a planned September webinar. • 2025–26 Funding & Access Model: o Additional £6.252 million in central funding secured to onboard 2,500 more patients. ▪ Approx. 500 paediatric, based on average new diagnoses under 18. ▪ 2,000 adults, with flexibility to adjust based on local demand. o A more flexible funding model is being implemented: ▪ Allocations are based on patient numbers, not specific device types. ▪ Boards must meet minimum onboarding targets but are free to allocate by local needs. o Funding covers pumps and CGM for under-18s; for adults, primarily pumps, though some flexibility remains. o Funding also supports: ▪ Continued operation of the National Onboarding Team. 2 ▪ Enhancements to SCI-Diabetes for better performance monitoring and reporting. • Strategic Notes: o Scotland has achieved over 70% of 30 + one clinical condition), NHS capacity cannot support universal access.